ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 520 • 2017 ACR/ARHP Annual Meeting

    Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach

    Norman Gaylis1, Joanne Sagliani1 and Steven Needell2, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2Boca Radiology, Boca Raton, FL

    Background/Purpose: Tofacitinib has been shown to reduce the clinical signs and symptoms of some RA patients at an approved dose of 5 mg bid. Studies…
  • Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting

    Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study

    David M. Brooks1, Michael Plotnick2, Nicola J. Williams3, Regina Kurrasch1, Yanli Zhuang2, Debra J. Tompson3, Benjamin Hsu2 and Ravi Rao3, 1GlaxoSmithKline, Collegeville, PA, 2Janssen Research & Development, LLC, Spring House, PA, 3GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose:   Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…
  • Abstract Number: 548 • 2017 ACR/ARHP Annual Meeting

    LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis

    Matthew Loza1, Androniki Bili2, Shruti Daga3, Kurt Brown4, Jennifer Gilbride5, Bidisha Dasgupta2, Benjamin Hsu2 and Iain B. McInnes6, 1Janssen Research & Development, LLC, Springhouse, PA, 2Janssen Research & Development, LLC, Spring House, PA, 3GlaxoSmithKline, Uxbridge, United Kingdom, 4GlaxoSmithKline, Collegeville, PA, 5Sum of Squares Ltd, Hertfordshire, United Kingdom, 6University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in RA in the phase…
  • Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting

    The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study

    Ingrid Louw1, Alan J. Kivitz2, Tsutomu Takeuchi3, Yoshiya Tanaka4, Satoshi Nakashima5, Jennifer Hodge6, Hong Tang6, Paula O'Connor6 and Barbara Finck6, 1Panorama Medical Centre, Cape Town, South Africa, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3Keio University School of Medicine, Tokyo, Japan, 4School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 5Daiichi Sankyo, Tokyo, Japan, 6Coherus BioSciences, Inc., Redwood City, CA

    Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
  • Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting

    Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials

    Bidisha Dasgupta1, Matthew Loza1, Androniki Bili1, Shruti Daga2, Kurt Brown3, Jennifer Gilbride4, Benjamin Hsu1 and Iain B. McInnes5, 1Janssen Research & Development, LLC, Spring House, PA, 2GlaxoSmithKline, Uxbridge, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Sum of Squares Ltd, Hertfordshire, United Kingdom, 5University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…
  • Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting

    Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

    Mark C. Genovese1, Josephine Glover2, Nobuhito Matsunaga3, Diane Chisholm4 and Rieke Alten5, 1Stanford University Medical Center, Palo Alto, CA, 2Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, 3Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, 4Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, 5University Medicine Berlin, Berlin, Germany

    Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
  • Abstract Number: 551 • 2017 ACR/ARHP Annual Meeting

    Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-

    Kosuke Ebina1, Makoto Hirao2, Motomu Hashimoto3, Moritoshi Furu4, Wataru Yamamoto5, Ryota Hara6, Takanori Fujimura6, Toru Hirano7, Shuzo Yoshida8, Koji Nagai8, Hideki Amuro9, Yonsu Son9, Akira Onishi10, Kengo Akashi11, Masaki Katayama12, Keiichi Yamamoto13 and Hideki Yoshikawa14, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Kurashiki Sweet Hospital, Okayama, Japan, 6The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan, 7Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 8Osaka Medical College, Osaka, Japan, 9Kansai Medical University, Osaka, Japan, 10Kobe University Graduate School of Medicine, Kobe, Japan, 11Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, 12Osaka Red Cross Hospital, Osaka, Japan, 13Osaka City University, Osaka, Japan, 14Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose:  More than 4 years have passed since 7 biologics became available for patients with rheumatoid arthritis (RA) in Japan, still lack reliable evidence in…
  • Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting

    Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Paul Studenic1, Farideh Alasti2, Daniel Aletaha3, Josef S. Smolen1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
  • Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting

    Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis

    Marita Zimmermann1, Elisabeth Vodicka2, Andrew J Holman3,4,5 and Louis P Garrison2, 1Constants in Global Health, University of Washington, Seattle, WA, 2Consultants in Global Health, University of Washington, Seattle, WA, 3Rheumatology, Pacific Rheumatology Associates Inc PS, Seattle, WA, 4Inmedix, Normandy Park, WA, 5Pacific Rheumatology Reseach, Seattle, WA

    Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…
  • Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting

    Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial

    Bidisha Dasgupta1, Kristen Sweet1, Dick DeVries2, Benjamin Hsu1, Ian Gourley1, Matthew Loza1 and Peter C. Taylor3, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Biologics Europe, Leiden, Netherlands, 3Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
  • Abstract Number: 1310 • 2017 ACR/ARHP Annual Meeting

    Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy

    Geneviève Genest1, Karen Spitzer2 and Carl Laskin3, 1Allergy-Immunology, McGill University and McGill University Health Center, Montreal, QC, Canada, 2Trio Fertility, Toronto, ON, Canada, 3Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during pregnancy but are frequently withheld in the second or third trimester to minimize transplacental transfer…
  • Abstract Number: 1394 • 2017 ACR/ARHP Annual Meeting

    Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort

    Richard Gliklich1, Zhaohui Su2, Gregory Donadio1, Tom Brecht2, Costas Boussios2, Francis O’Donovan3, Charles Kekeh3, Anna Lafontant2, Kathryn Starzyk2 and Vandana Menon2, 1OM1, Inc, Cambridge, MA, 2Research, OM1, Inc, Cambridge, MA, 3Data Science, OM1, Inc, Cambridge, MA

    Background/Purpose: RA is estimated to affect approximately 1.3 million adults in the US and accounts for a significant proportion of US health care spend with…
  • Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting

    The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA)  for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis

    Daniela Sieghart1, Farideh Alasti2, Paul Studenic1 and Günter Steiner2, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
  • Abstract Number: 1444 • 2017 ACR/ARHP Annual Meeting

    Targeted Therapeutic Delivery to Cartilage with Knottin Proteins

    Emily Girard, Michelle Cook Sangar, Gene Hopping, Fiona Pakiam and James Olson, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

    Background/Purpose: Arthritic diseases affect more than 50 million Americans and, although there are many etiologies, the common manifestation of the disease is pain and limited…
  • Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting

    Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)

    Dolores Ramos-Bello1, Crisol Alvarez-Quiroga2, Georgina Aguilera Barragán-Pickens3, Angel Javier Pedro Martínez3, Tania Adriana Luna-Zúñiga3, Georgina Martínez-Flores3, Eduardo Saul Acevedo-Castañeda4, Homero López-Ferretis3, Enrique Cuevas-Orta3, Eva Santillan-Guerrero3, Ricardo Moreno-Valdez3, Martín Saldaña-Baarnard3, Marco Ulises Martinez-Martinez5, David Herrera Van Oostdam6, Roberto González-Amaro7 and Carlos Abud-Mendoza8, 1Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, 2División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, 3Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 4Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 5Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 6Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 7Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 8Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

    Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology